Mel Hardman

Pregnancy In Clinical Trials: Janssen Accepts The Challenge, Sees Value Beyond Maternal-Fetal Health Janssen's Katie Abouzahr, MD, discusses the nuances of enrolling pregnant participants in clinical trials and considerations for future maternal-fetal disease research. Study Completes Recruitment, Overcomes Pandemic Hurdles Amid challenges during the COVID-19 pandemic, discover how recruitment was completed in three countries for a Sweden-based pharmaceutical company's Phase 2b study.

By Mel Hardman, DrPH, founder and principal strategist, Faces of Research Technology, including telehealth visits, mobile applications, and wearables, helps researchers reach more people. However, it alone doesn’t alleviate the lack of diversity in clinical trials.1 Once diverse patients are reached, how do we get them to feel safe, have trust, and be interested in participating in something they likely know very little about? With cultural competency.